Search

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

About our Innovation Prize

Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.

Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US

Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Propeller Health & BI Announce New Partnership | BI US

Propeller Health, the leading digital health solution for respiratory medicine and BI announce new partnership to help people living with COPD & asthma.

Boehringer Ingelheim and Junior Achievement: A decade of inspiring futures

Boehringer Ingelheim celebrates its decade-long partnership and volunteering milestone.

Medical Affairs & Scientific Comms. | Boehringer Ingelheim US

Boehringer Ingelheim is proud to offer a 2-year, rotation-based, Fellowship program within Medical Affairs & Scientific Communications.

Patient Week 2024 demonstrates importance of #PatientPoweredProgress

Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Our People, Our Culture

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

Citizen Petition

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

Our Mission

Our Story

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Pharmacy Rotations

Click here to read testimonies from our employees who enrolled in our pharmacy rotations academic program.

Corporate Compliance Program

Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

BI Cares Financial Contributions Program: Strengthening Communities

Boehringer Ingelheim: Discover the app set to transform animal care in rural India

Learn about the app set to transform animal care in rural India. Women will be empowered and goat welfare will be promoted. From idea to app!

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

Making Toys for Shelter Animals | Boehringer Ingelheim US

Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.

An Employee’s Commitment to Ensuring Access to Medicines

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers